Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (NCT03715933)
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 12 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- HonorHealth Research Institute — Scottsdale, Arizona
- Precision NextGen Oncology and Research — Beverly Hills, California
- City of Hope — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California, San Diego (UCSD) - Moores Cancer Center — San Diego, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Sarcoma Oncology Center — Santa Monica, California
- University of Colorado Hospital — Aurora, Colorado
- Emory University - Winship Cancer Institute — Atlanta, Georgia
- The University of Chicago — Chicago, Illinois
- University of Michigan — Ann Arbor, Michigan
- START Midwest Michigan, PC — Grand Rapids, Michigan
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health & Science University — Portland, Oregon
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research — Philadelphia, Pennsylvania
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- Vanderbilt University School of Medicine — Nashville, Tennessee
- UT MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
- University of Virginia — Charlottesville, Virginia
- NEXT Oncology - Virginia — Fairfax, Virginia
- Centre Leon Berard — Lyon,
- Gustave Roussy — Villejuif,
📞 Contact the Study Coordinator
Phone: (858) 500-7833
Email: clinicaltrials@inhibrx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ewing Sarcoma
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors — Birmingham, Alabama
- Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD — Los Angeles, California
- RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT — Houston, Texas
- EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT — Cleveland, Ohio
- Lurbinectedin in FET-Fused Tumors — Los Angeles, California
Explore by condition: All Ewing Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.